
CareDx, Inc
CDNANASDAQHealthcareMedical - Diagnostics & Research
前收盘价
US$48.61
+US$1.62 · +3.45%
盘前
US$48.75
+US$0.14 · +0.29%
8月24日 4:49 ET
CDNA公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Sell
Trim exposure — unfavorable risk-reward
估值
8
Overpriced
动量
70
Gaining
情绪
57
Mixed
风险韧性
44
Elevated Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
- 行业
- Medical - Diagnostics & Research
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- John Walter Hanna Jr.
- 上市以来
- 2014年7月17日
- 雇员
- 763
市场位置
日内区间
当前US$48.61,
52周区间
当前US$48.61,
- 开盘价
- US$46.99
- 前收盘价
- US$46.99
- 成交量
- 116.05万
- 1.19× 平均值
- 平均成交量
- 97.88万
- 日均成交量
- 市值
- 25.15亿 USD
- 贝塔
- 2.42
- 市场参考 1
- 50天平均值
- US$35.671
- 高于平均水平+36.27%
- 200天平均值
- US$23.3534
- 高于平均水平+108.15%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 9.65亿 USD
- 市盈率(TTM)
- 22.59×
- 市净率(TTM)
- 5.88×
- 市销率(TTM)
- 5.49×
- EV/EBITDA
- -207.24×
- 盈利收益率
- -2.13%
- 自由现金流收益率
- 3.60%
- 股息率
- 0.00%
盈利能力和效率
- 毛利率
- 70.58%
- 营业利润率
- -0.92%
- 净利润率
- 24.23%
- 净资产收益率
- -7.05%
- 资产收益率
- -5.17%
- 投入资本回报率
- -7.60%
财务健康
- 负债权益比
- 0.05×
- 流动比率
- 2.86×
财报历史与展望
- 最新财年每股收益
- -0.4
- 2025财年 · 同比-143.01%
- 最新财年收入
- 3.8亿 USD
- 2025财年 · 同比+13.79%
- 下一财年每股收益共识
- 1.21
- 2026财年 · 4位分析师
- 下一财年收入共识
- 4.95亿 USD
- 2026财年 · 5位分析师
年度每股收益趋势
已公布业绩及可用的市场共识预期。
年度营收趋势
已公布业绩及可用的市场共识预期。
分析师评级
第三方分析师预期可能变化,并非 GoAI 建议。
评级分布
13项评级CDNA 消息
CDNA同业公司
持有CDNA的ETF
报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG7403.18万3.57%15.57亿 USD0.75%US$49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI6812.42万0.00%2.3万亿 USD0.03%US$378.24+0.44%
iShares Russell 2000 ETFIWM6207.22万0.08%816.21亿 USD0.19%US$299.96+0.77%
State Street SPDR S&P Biotech ETFXBI5639.3万0.49%113.95亿 USD0.35%US$165.73+1.44%
Vanguard Extended Market ETFVXF2604.71万0.03%937亿 USD0.05%US$245.53+0.82%
iShares Russell 2000 Growth ETFIWO2224.56万0.15%151.65亿 USD0.24%US$387.37+1.24%
Invesco Biotechnology & Genome ETFPBE1998.4万5.02%4.02亿 USD0.58%US$97.59+1.07%
iShares Biotechnology ETFIBB1640.82万0.15%107.45亿 USD0.44%US$213.56+1.29%
ARK Genomic Revolution ETFARKG- 市场价值
- 7403.18万
- 重量
- 3.57%
- AUM
- 15.57亿 USD
- 费用率
- 0.75%
- 价格 / 1日
- US$49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI- 市场价值
- 6812.42万
- 重量
- 0.00%
- AUM
- 2.3万亿 USD
- 费用率
- 0.03%
- 价格 / 1日
- US$378.24+0.44%
iShares Russell 2000 ETFIWM- 市场价值
- 6207.22万
- 重量
- 0.08%
- AUM
- 816.21亿 USD
- 费用率
- 0.19%
- 价格 / 1日
- US$299.96+0.77%
State Street SPDR S&P Biotech ETFXBI- 市场价值
- 5639.3万
- 重量
- 0.49%
- AUM
- 113.95亿 USD
- 费用率
- 0.35%
- 价格 / 1日
- US$165.73+1.44%
Vanguard Extended Market ETFVXF- 市场价值
- 2604.71万
- 重量
- 0.03%
- AUM
- 937亿 USD
- 费用率
- 0.05%
- 价格 / 1日
- US$245.53+0.82%
iShares Russell 2000 Growth ETFIWO- 市场价值
- 2224.56万
- 重量
- 0.15%
- AUM
- 151.65亿 USD
- 费用率
- 0.24%
- 价格 / 1日
- US$387.37+1.24%
Invesco Biotechnology & Genome ETFPBE- 市场价值
- 1998.4万
- 重量
- 5.02%
- AUM
- 4.02亿 USD
- 费用率
- 0.58%
- 价格 / 1日
- US$97.59+1.07%
iShares Biotechnology ETFIBB- 市场价值
- 1640.82万
- 重量
- 0.15%
- AUM
- 107.45亿 USD
- 费用率
- 0.44%
- 价格 / 1日
- US$213.56+1.29%
继续GoAI的研究
在 GoAI 中研究CDNAresearch.disclaimer











